1/13/2024 0 Comments Triple negative breast cancerTreatment with olaparib or chemotherapy continued until disease progression or unacceptable toxicity. Researchers then assigned patients who achieved complete response, partial response or stable disease after four to six treatment cycles to either 200 mg pembrolizumab once every 3 weeks plus 300 mg twice daily olaparib (n = 135), or to pembrolizumab plus chemotherapy (n = 136). Study participants underwent induction therapy for up to six cycles of pembrolizumab dosed at 200 mg plus carboplatin area under the curve 2 combined with 1,000 mg/m² gemcitabine on days 1 and 8 every 3 weeks. All patients also had measurable, locally recurrent inoperable or metastatic disease not previously treated with chemotherapy in the metastatic setting. The randomized phase 2 KEYLYNK-009 included 271 patients with locally recurrent inoperable or metastatic triple-negative breast cancer.Īll patients derived clinical benefit from first-line treatment with pembrolizumab - an anti-PD-1 therapy - plus platinum-based chemotherapy. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at UCSF Helen Diller Comprehensive Cancer Center, and colleagues wrote. “The inhibitor olaparib is an established maintenance therapy for multiple platinum-sensitive tumor types, and prior data suggest that PARP inhibitors combined with PD-1/PD-L1 inhibitors could provide an improved therapeutic effect, ” Hope S. However, a need remains for safe and effective treatments after induction to sustain the clinical benefit. Rationale and methodsĪs Healio previously reported, results of the KEYNOTE-355 trial showed the addition of pembrolizumab to first-line chemotherapy significantly extended PFS and OS among patients with PD-L1-positive metastatic triple-negative breast cancer. However, patients with BRCA mutations did achieve longer PFS and OS with pembrolizumab (Keytruda, Merck) plus olaparib (Lynparza, AstraZeneca), suggesting a potential maintenance strategy for that subgroup, researchers concluded. Pembrolizumab plus olaparib did not improve outcomes among patients with locally recurrent inoperable or metastatic triple-negative breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |